Kairos Pharma Reports Positive Phase 2 Results for Prostate Cancer Treatment

Key Facts

1Kairos Pharma announced positive and statistically significant interim efficacy data from its Phase 2 trial of ENV-105.

Kairos Pharma announced positive and statistically significant interim efficacy data from its Phase 2 trial of ENV-105. The company stated in a Business Wire release that the interim analysis of the ongoing clinical trial reached a point of statistical significance regarding the drug's efficacy in treating drug-resistant cancer.

The data showed that ENV-105, in combination with apalutamide, demonstrated a significant difference in progression-free survival (PFS) for patients with metastatic prostate cancer. KAPA closed at $1.55 on October 5, 2026, having reached a day high of $1.59 and a low of $1.52 during that session.